Journey Medical (DERM) revenue breakdown
By product, Qbrexza is the largest at 41% of fiscal 2025 revenue; Accutane grew fastest, 9% a year over 3 years.
Revenue by product
Fiscal years, as Journey Medical reports them in its 10-K filings; fiscal 2025 total $61M.
| Products | 2020 | 2021 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|
| Qbrexza | — | — | $25M | $25M | $25M | 41% |
| Emrosi | — | — | — | — | $15M | 24% |
| Accutane | — | $10M | $20M | $19M | $13M | 21% |
| Foam franchise products (Amzeeq & Zilxi) | — | — | — | $7M | $6M | 10% |
| Other / legacy | — | — | $6M | $4M | $3M | 4% |
| Targadox | $31M | $22M | — | — | — | — |
| Qbrexa | — | $17M | — | — | — | — |
| Ximino | $10M | $8M | — | — | — | — |
| Amzeeq | — | — | $6M | — | — | — |
| Exelderm | $4M | $5M | — | — | — | — |
| Zilxi | — | — | $2M | — | — | — |
| Other branded products | -$148,000 | $37,000 | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for DERM.
Open DERM in InvestinglyQuestions
Where does Journey Medical make its money?
In fiscal 2025, by product: Qbrexza $25M, Emrosi $15M, Accutane $13M, Foam franchise products (Amzeeq & Zilxi) $6M, Other / legacy $3M.
From Journey Medical's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.